Paratiroid Hastalıklarında Nükleer Tıp Yöntemleri
Özet
Paratiroid bezi endokrin sistemde kalsiyum metabolizması üzerinde önemli role sahip olup, paratiroid adenomları primer hiperparatiroidinin (PHPT) ana sorumlusudur. Cerrahi öncesinde hiperfonksiyonel bezlerin kesin lokalizasyonu, cerrahi başarının artırılması ve operasyon konforu açısından büyük öneme sahiptir. Geleneksel iki boyutlu planar paratiroid sintigrafisinden hibrit SPECT/BT ve PET/BT gibi üç boyutlu modalitelere geçiş, fonksiyonel ve morfolojik verileri birleştirerek anatomik lokalizasyonda büyük başarı sağlamıştır. Tc-99m MIBI, paratiroid sintigrafisinde en yaygın kullanılan radyofarmasötik olup çift izotop veya çift faz görüntüleme protokolleriyle uygulanabilmektedir. Çift fazlı görüntülemede SPECT/BT kullanımı, özellikle ektopik bezlerin saptanmasında planar ve standart SPECT yöntemlerine kıyasla üstün doğruluğa sahiptir. Son yıllarda öne çıkan F-18 florokolin ve C-11 metiyonin gibi PET/BT ajanları, yüksek uzaysal çözünürlükleri ve kısa çekim süreleriyle küçük lezyonların tespitinde yüksek sensitivite sergilemektedir. Birinci basamak yöntemlerin yetersiz veya negatif kaldığı karmaşık ya da tekrarlayan vakalarda; PET/BT, PET/MR ve 4D-BT gibi ileri ikinci basamak görüntüleme teknolojileri cerrahiye rehberlik etmede kritik avantajlar sunmaktadır.
The parathyroid gland plays a central role in regulating calcium metabolism, and parathyroid adenomas account for most primary hyperparathyroidism (PHPT) cases. Precise preoperative localization of hyperfunctioning glands is essential for guiding successful surgical interventions and achieving long-term cure. The technological shift from two-dimensional planar scintigraphy to three-dimensional hybrid modalities like SPECT/CT and PET/CT has revolutionized endocrine diagnosis by successfully combining functional and morphological data. Technetium-99m MIBI is the most widely utilized radiopharmaceutical in parathyroid scintigraphy, routinely applied via dual-isotope or dual-phase imaging protocols. Integrating SPECT/CT into dual-phase protocols offers superior diagnostic accuracy over planar methods, proving exceptionally beneficial for identifying ectopic glands. Recently, PET/CT imaging with positron-emitting tracers such as F-18 fluorocholine and C-11 methionine has demonstrated excellent sensitivity in detecting tiny lesions owing to higher spatial resolution and shorter acquisition times. In complex or recurrent cases where first-line modalities yield negative or inconclusive findings, advanced second-line techniques including PET/CT, PET/MRI, and 4D-CT offer vital diagnostic guidance for revision surgeries.
Referanslar
Nakaoka D, Sugimoto T, Kobayashi T, Yamaguchi T, Kobayashi A, Chihara K. Evaluation of changes in bone density and biochemical parameters after parathyroidectomy in primary hyperparathyroidism. Endocr J. 2000 Jun;47(3):231-7
Lavely WC, Goetz S, Friedman KP, et al. Comparison of SPECT/CT, SPECT, and planar imaging with single-and dual-phase (99m) Tc-sestamibi parathyroid scintigraphy. J Nucl Med. 2007;48:1084– 1089
Modarai B, Sawyer A, Ellis H. The glands of Owen. J R Soc Med. 2004 Oct;97(10): 494-5.
Eslamy HK, Ziessman HA. Parathyroid scintigraphy in patients with primary hyperparathyroidism: 99mTc sestamibi SPECT and SPECT/CT. Radiographics. 2008 Sep-Oct;28(5):1461-76.
Akerström G, Malmaeus J, Bergström R. Surgical anatomy of human parathyroid glands. Surgery. 1984 Jan;95(1):14-21.
Mihai R, Farndon JR. Parathyroid disease and calcium metabolism. Br J Anaesth, 2000;85(1):29‐43.
Morland D, Lalire P, Deguelte S, Zalzali M, Richard C, Dejust S, Boulagnon C, Ly S, Papathanassiou D, Delemer B. Added value of 18F-fluorocholine positron emission tomography-computed tomography in presurgical localization of hyperfunctioning parathyroid glands after dual tracer subtraction scintigraphy failure: A retrospective study of 47 patients. Medicine (Baltimore). 2020 Jan;99(2):e18681.
Felger EA, Kandil E. Primary hyperparathyroidism. Otolaryngol Clin North Am. 2010 Apr;43(2):417-32
Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009 Feb;94(2):351-65.
Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018 Jan 13;391(10116):168-178
Sociedade Brasileira de Endocrinologia e Metabologia, Bandeira F, Griz L, Chaves N, Carvalho NC, Borges LM, Lazaretti-Castro M, Borba V, Castro LC, Borges JL, Bilezikian J. Diagnosis and management of primary hyperparathyroidism--a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. Arq Bras Endocrinol Metabol. 2013 Aug;57(6):406-24.
Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, Dempster D, Lewiecki EM, Liu JM, Minisola S, Rejnmark L, Silva BC, Walker MD, Bilezikian JP. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014 Oct;99(10):3580-94.
Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014 Oct;99(10):3561-9.
Applewhite MK, Schneider DF. Mild primary hyperparathyroidism: a literature review. Oncologist. 2014 Sep;19(9):919-29.
Aojula N, Khan S, Gittoes N, Hassan-Smith Z. Normocalcaemic primary hyperparathyroidism: what is the role of parathyroid surgery? Ther Adv Endocrinol Metab. 2021 Feb 27;12:2042018821995370.
Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014 Oct;99(10):3570-9.
Qin X, Wang B, Li B, Lin C, Liu X, Xie X. Value of contrast-enhanced ultrasonography in radiofrequency ablation of secondary hyperparathyroidism. Ren Fail. 2021 Dec;43(1):445-451.
Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Semin Nucl Med. 2005 Oct;35(4):266-76.
Fuster D, Torregrosa J-V, Domenech B, Solà O, Martín G,Casellas J, et al. Dual-phase 99mTc-MIBI scintigraphy to assess calcimimetic effect in patients on haemodialysis with secondary hyperparathyroidism. Nucl Med Commun. 2009 Nov [cited 2020
Taïeb D, Ureña-Torres P, Zanotti-Fregonara P, Rubello D, Ferretti A, Henter I, et al. Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT. Clin Nucl Med. 2013 Aug [cited 2020 Apr 26];38(8):630–5
Roef M, Vogel W V. The effects of muscle exercise and bed rest on [18F]methylcholine PET/CT. Eur J Nucl Med Mol Imaging. 2011 Mar [cited 2019 Dec 12];38(3):526–30.
Coakley A, Kettle A, Wells C, O'doherty M, Collins R. 99Tcm sestamibi-a new agent for parathyroid imaging. Nucl Med Commun. 1989;10(11):791–4.
Bugis SP, Berno E, Rusnak CH, Chu D. Technetium99m-sestamibi scanning before initial neck exploration in patients with primary hyperparathyroidism. Eur Arch Otorhinolaryngol. 1995;252(3):149-52.
Hetrakul N, Civelek AC, Stagg CA, Udelsman R. In vitro accumulation of technetium-99m-sestamibi in human parathyroid mitochondria. Surgery. 2001 Dec;130(6):1011-8.
Hindié E, Ugur O, Fuster D, O'Doherty M, Grassetto G, Ureña P, Kettle A, Gulec SA, Pons F, Rubello D; Parathyroid Task Group of the EANM. 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1201-16.
Greenspan BS, Dillehay G, Intenzo C, Lavely WC, O'Doherty M, Palestro CJ, Scheve W, Stabin MG, Sylvestros D, Tulchinsky M. SNM practice guideline for parathyroid scintigraphy 4.0. J Nucl Med Technol. 2012 Jun;40(2):111-8.
Pelletier-Galarneau M, Sogbein OO, Dinh L, Zuckier LS. Superiority of digital subtraction for analysis of simultaneously-acquired dual-radiopharmaceutical parathyroid scintigraphy. Open J Med Imaging. 2015;5(2):7
Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med. 1992;33(10):1801–7.
Froberg AC, Valkema R, Bonjer HJ, Krenning EP. 99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy? Eur J Nucl Med Mol Imaging. 2003;30(2):193–6.
Caveny SA, Klingensmith WC III, Martin WE, Sage-El A, McIntyre RC Jr, Raeburn C, Wolfe P. Parathyroid imaging: the importance of dual-radiopharmaceutical simultaneous acquisition with 99mTc-sestamibi and 123I. J Nucl Med Technol. 2012;40(2):104.
Hindie E, Melliere D, Jeanguillaume C, Perlemuter L, Chehade F, Galle P. Parathyroid imaging using simultaneous double-window recording of technetium-99m-sestamibi and iodine-123. J Nucl Med. 1998;39(6):1100–5).
Caixàs A, Bernà L, Piera J, Rigla M, Matías-Guiu X, Farrerons J, Puig-Domingo M. Utility of 99mTc-sestamibi scintigraphy as a first-line imaging procedure in the preoperative evaluation of hyperparathyroidism. Clin Endocrinol (Oxf). 1995 Nov;43(5):525-30.
O'Doherty MJ, Kettle AG, Wells P, Collins R, Coakley AJ. Parathyroid imaging with technetium- 99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med. 1992;33(3):313–8.)
Bénard F, Lefebvre B, Beuvon F, Langlois M-F, Bisson G. Rapid washout of technetium-99m-MIBI from a large parathyroid adenoma. J Nucl Med. 1995;36(2):241–3
Neumann DR, Obuchowski NA, Di ilippo FP. Preoperative 123I/99mTc-sestamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism. J Nucl Med. 2008;49(12):2012–7.
Pelletier-Galarneau M, Sogbein B, Zuckier L. Coimaging of 123I-NaI can be eliminated from the scintigraphic evaluation of parathyroid adenoma with only minimal effect on inal imaging diagnosis. J Nucl Med. 2013;54(Suppl 2):147.
Thomas DL, Bartel T, Menda Y, Howe J, Graham MM, Juweid ME. Single photon emission computed tomography (SPECT) should be routinely performed for the detection of parathyroid abnormalities utilizing technetium-99m sestamibi parathyroid scintigraphy. Clin Nucl Med. 2009;34(10):651–5
Treglia G, Sadeghi R, Schalin-Jäntti C, Caldarella C, Ceriani L, Giovanella L, et al. Detection rate of 99m Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: a metaanalysis. Head Neck. 2016 Apr 1 [cited 2019 Nov 7];38(S1): E2159–72.
Alexandrides T, Spiliotis J, Nikiforidis G, Vlachojannis JG, Vassilakos PJ. Technetium-99m-tetrofosmin for parathyroid scintigraphy: comparison to thallium-technetium scanning. J Nucl Med. 1998 Aug;39(8):1433-41.
Liddy S, Worsley D, Torreggiani W, Feeney J. Preoperative imaging in Primary hyperparathyroidism: literature review and recommendations. Can Assoc Radiol J. 2017;68(1):47–5
Petranović Ovčariček P, Giovanella L, Carrió Gasset I, Hindié E, Huellner MW, Luster M, Piccardo A, Weber T, Talbot JN, Verburg FA. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021 Apr 10. doi: 10. 1007/s00259-021-05334
Bioletto F, Barale M, Parasiliti-Caprino M, Prencipe N, Berton AM, Procopio M, Deandreis D, Ghigo E. Comparison of the diagnostic accuracy of 18F-Fluorocholine PET and 11C-Methionine PET for parathyroid localization in primary hyperparathyroidism: a systematic review and meta-analysis. Eur J Endocrinol. 2021 Apr 1:EJE-21-0038.R1. doi: 10.1530/EJE-21-0038.
Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 2007; 37:400–419.
Cuderman A, Senica K, Rep S, Hocevar M, Kocjan T, Sever MJ, et al. 18F-fluorocholine PET/CT in primary hyperparathyroidism: superior diagnostic performance to conventional scintigraphic imaging for localization of hyperfunctioning parathyroid glands. J Nucl Med. 2020 Apr [cited 2020 Jul 14];61(4):577–83.
Imperiale A, Taïeb D, Hindié E. 18F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism. Eur J NuclMedMol Imaging. 2018 Apr 15 [cited 2019 Nov 7];45(4):654–7.
Kluijfhout WP, Pasternak JD, Gosnell JE, Shen WT, Duh Q-Y, Vriens MR, et al. 18 F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study. Radiology. 2017 Aug 25 [cited 2020 Apr 21];284(2):460–7.
